ArticleBiochimie2025
Regulation of ferroptosis by transcription factor E2F1.
Article in Biochimie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis.Cancer research · 2026Article
- Cell size modulates ferroptosis susceptibility.eLife · 2026Article
- Multiplexed Transcriptomics for Screening Drug Combinations and Defining the Mechanism of Action of HCC Therapeutics at Single-Cell Resolution.Cell proliferation · 2026Article
- Inhibition of RBM23 induces ferroptosis in colon cancer cells via c-Myc regulation.Cancer cell international · 2026Article
- Cell size modulates ferroptosis susceptibility.bioRxiv : the preprint server for biology · 2026Article
- Ferroptosis in Spine-Related Diseases: Mechanistic Insights and Potential Therapeutic Targets.Cellular and molecular neurobiology · 2026Review
- Targeting LxCxE Cleft Pocket of Retinoblastoma Protein in Immunosuppressive Macrophages Inhibits Ovarian Cancer Progression.Cancer immunology research · 2025Article
- ZFP36 promotes ferroptosis and mitochondrial dysfunction and inhibits malignant progression in osteosarcoma by regulating the E2F1/ATF4 axis.Journal of pharmaceutical analysis · 2025Article
- PSMD14/E2F1 Axis-Mediated CENPF Promotes the Metastasis of Triple-Negative Breast Cancer Through Inhibiting Ferroptosis.Cancer science · 2025Article
- Phosphorylation State of RB Modulates Ferroptotic Sensitivity.Cell biochemistry and function · 2025Article
- ACSS2 regulates ferroptosis in an E2F1-dependent manner in breast cancer brain metastatic cells.bioRxiv : the preprint server for biology · 2024Article
- FSP1 is a predictive biomarker of osteosarcoma cells' susceptibility to ferroptotic cell death and a potential therapeutic target.Cell death discovery · 2024Article
Corrections and comments
- Update of
Authors and funding
5 authors.
Funding
Abstract
The E2F family of transcription factors plays multiple roles in cell cycle regulation. E2F can be inhibited by binding to RB proteins, an interaction that is regulated by CDK phosphorylation of RB. We previously observed that CDKs, RB, and E2F regulate ferroptosis, a type of programmed cell death characterized by catastrophic peroxidation of membrane lipids. Here we investigate the impact of E2F on ferroptosis. E2F1 regulates both pro and anti-ferroptotic proteins including ALOX5, MYC, SLC7A11, ATF4, and GPX4 and finally renders a net inhibitory role in ferroptosis. Interestingly, we also obtained evidence for a cell type dependent compensatory effect of E2F3 upon E2F1 depletion. Specifically, downregulation of ferroptotic genes upon E2F1 knockdown fails to occur in an osteosarcoma cell line which upregulates E2F3 under these conditions. Taken together, our study identifies a number of E2F targets with the potential to affect ferroptotic sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.